Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (161-170 of 288) with videos related to

Pageof 29
Sort By:
Medicine|October 30, 2015
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/RibavirinSabrina Bagaglio, Caterina Uberti-Foppa, Clelia Di Serio, et al.
AIDS (London, England)|March 22, 2006
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna, Anna Danise, Stefano Menzo, et al.
Plos One|February 17, 2018
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral loadNadia Galizzi, Laura Galli, Andrea Poli, et al.
The New Microbiologica|July 23, 2005
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti, Elena Seminari, Monica Guffanti, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairmentElena Seminari, Anna De Bona, Gianluca Gentilini, et al.
Journal of the International AIDS Society|August 2, 2015
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapyNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
AIDS (London, England)|June 29, 2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni, Nicola Gianotti, Vincenzo Spagnuolo, et al.
Lancet (London, England)|April 17, 2007
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialBeatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, et al.
The Journal of Clinical Investigation|March 6, 2002
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapyG Paolo Rizzardi, Alexandre Harari, Brunella Capiluppi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2018
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological SuppressionCamilla Muccini, Laura Galli, Andrea Poli, et al.
Pageof 29

Showing results (161-170 of 288) with videos related to

Sort By:
Pageof 29
Medicine|October 30, 2015
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/RibavirinSabrina Bagaglio, Caterina Uberti-Foppa, Clelia Di Serio, et al.
AIDS (London, England)|March 22, 2006
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna, Anna Danise, Stefano Menzo, et al.
Plos One|February 17, 2018
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral loadNadia Galizzi, Laura Galli, Andrea Poli, et al.
The New Microbiologica|July 23, 2005
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti, Elena Seminari, Monica Guffanti, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairmentElena Seminari, Anna De Bona, Gianluca Gentilini, et al.
Journal of the International AIDS Society|August 2, 2015
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapyNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
AIDS (London, England)|June 29, 2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni, Nicola Gianotti, Vincenzo Spagnuolo, et al.
Lancet (London, England)|April 17, 2007
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialBeatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, et al.
The Journal of Clinical Investigation|March 6, 2002
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapyG Paolo Rizzardi, Alexandre Harari, Brunella Capiluppi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2018
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological SuppressionCamilla Muccini, Laura Galli, Andrea Poli, et al.
Pageof 29